FDG-PET Use In Oncology Procedures Shows Promise, Limits - RSNA Studies
This article was originally published in The Gray Sheet
Positron emission tomography (PET) in conjunction with the imaging agent F-18 fluorodeoxyglucose (FDG) holds promise as a less invasive alternative to existing options in the regional staging of patients with newly diagnosed melanoma, according to a study by Puneet Singha, MD, et al., University Hospital of Cleveland.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.